skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Would you have any recommendations on this company?

Thanks,
Read Answer Asked by Bryan on February 27, 2020
Q: Please give me your opinion about PLUG,PWFL,VSLR, AGYS for next three to five years.

Thanks,
Read Answer Asked by vipin on February 27, 2020
Q: I have $4,200 "invested" in WILD , in my TFSA account. Currently I am down $3,600 with only $600 residual value. Thinking of accepting the full loss, selling and putting the $600 to some other use but wonder if I'm better off just holding on at this point. With no tax loss benefit, which way would you go here?
Thanks for your thoughts,
Mark
Read Answer Asked by Mark on February 26, 2020
Q: I have a "friend" promoting this stock. I am always leery of these "tips" but admit I do look into them to see if there is any potential merit in a speculative play. I cannot find any meaningful info on this company. Can you share with me what you know about it.
Thanks John
Read Answer Asked by John on February 26, 2020
Q: After a recent run to $2.75 H on Jan 16,STC retreated to $2.38 on Jan 21.Any reason? Is this a good point to add to my 1% position(p/p $2.47)especially in light of the sharp drop in Asian markets & U.S. futures today? Also your expectations of eps & revenue of its Q2 on Feb 27. Txs for u usual great services & views Looking forward to seeing Ryan on BNN,Feb 26
Read Answer Asked by Peter on February 24, 2020
Q: While you have not been particularly enthusiastic to this point, I would appreciate your analysis of their latest results. Clearly the market was very impressed as it cracked both the highest gainers and most heavily traded lists yesterday.

BEVERLY, Mass. and TORONTO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading global provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today reported preliminary selected unaudited financial results for the fourth quarter and year ended December 31, 2019.

Based on preliminary unaudited results, 2019 revenues increased 21% to a record $35.3 million with adjusted EBITDA for the year of approximately $7.1 million (14.6% year over year growth). Fourth quarter sales increased 34% to $10.8 million, with adjusted EBITDA estimated to increase 27% to approximately $2.2 million. Organic growth on a constant currency basis was approximately 15% for the year and approximately 20% in the fourth quarter, largely driven by sales increases of equipment and consumables. Gross profit margins were approximately 53.8% for the year and 56.4% for the fourth quarter.
Read Answer Asked by karl on February 20, 2020
Q: Hello,looking to buy, could you comment for growth and income.(Do like its portfolio of companies). It looks like a $ 4.25 target price? Or would you consider it too risky?
Would you recommend an alternative in the 5%
distribution range. Looking for growth with some safety.
Read Answer Asked by Brad on February 20, 2020
Q: Hi 5i Team. Thanks for your great service.
With all the renewed hype with regards to green/ESG companies, is there a need to own all of the above companies or do their services overlap? Which ones would you own?

Thanks

Dave.
Read Answer Asked by David on February 19, 2020
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!